iBio Announces New Investments from Board Members and Officers
01/13/25, 12:30 PM
Location
bryanMoney
$650,000
Industry
biotechnology
manufacturing
Type
partnership
iBio, Inc. announced the closing of a private placement offering with members of its Board of Directors and Officers, totaling over $650,000. This investment underscores the confidence and support in iBio's strategy to advance as a clinical-stage biotech focused on developing therapeutics for cardiometabolic diseases, obesity, and other challenging diseases.
Company Info
Location
hsc pkwy
bryan, texas, united states
Additional Info
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of hard-to-target subdominant epitopes along with its sustainable, plant-based protein expression capabilities for cGMP manufacturing. Its FastPharming® Manufacturing System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic, infectious and autoimmune diseases. The Company’s wholly owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringTM Development Services for advanced recombinant protein engineering.